1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study

Fertility and Sterility

Volumn 93, Issue 3, 2010, Pages 847-854

  Humaidan, Peter ^a   Ejdrup Bredkjær, Helle ^b   Westergaard, Lars Grabow ^c   Yding Andersen, Claus ^d  

^a SKIVE REGIONAL HOSPITAL   (Denmark)

^b HOLBÆK HOSPITAL   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d Mental Health Services CPH   (Denmark)

Author keywords

GnRH agonist; GnRH antagonist; hCG; IVF; ovulation induction

Indexed keywords

BUSERELIN; CHORIONIC GONADOTROPIN; GANIRELIX; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELIVERY; FEMALE; FERTILIZATION IN VITRO; HORMONE BLOOD LEVEL; HUMAN; INTRACYTOPLASMIC SPERM INJECTION; LUTEAL PHASE; MAJOR CLINICAL STUDY; OOCYTE MATURATION; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; OVULATION INDUCTION; PREGNANCY RATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; BLASTOCYST; CHORIONIC GONADOTROPIN; ESTRADIOL; FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HUMANS; LUTEAL PHASE; LUTEINIZING HORMONE; OOCYTE RETRIEVAL; OOCYTES; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY OUTCOME; PROGESTERONE; PROSPECTIVE STUDIES; REPRODUCTIVE CONTROL AGENTS; SPERM INJECTIONS, INTRACYTOPLASMIC;

EID: 75749138165     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2008.12.042     Document Type: Article

References (35)

1. Albano C., Smitz J., Camus M., Riethmuller-Winzen H., Van Steirteghem A., and Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 67 (1997) 917-922
2. Itskovitz-Eldor J., Kol S., Mannaerts B., and Coelingh Bennink H. First established pregnancy after controlled ovarian hyperstimulation with recombinant follicle stimulating hormone and gonadotrophin-releasing hormone antagonist ganirelix (Org 37462). Hum Reprod 13 (1998) 294-295
3. Borm G., Mannaerts B., and European Orgalutran Study Group. Treatment with the gonadotropin-releasing hormone antagonist ganirelix in women undergoing controlled ovarian hyperstimulation with recombinant follicle stimulating hormone is effective, safe and convenient. Hum Reprod 49 (2000) 118-122
4. Nakano R., Mizuno T., Kotsuji F., Katayama K., Wshio M., and Tojo S. "Triggering" of ovulation after infusion of synthetic luteinizing hormone releasing factor (LRF). Acta Obstet Gynecol Scand 52 (1973) 269-272
5. Gonen Y., Balakier H., Powell W., and Casper R.F. Use of GnRH agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 71 (1990) 918-922
6. Itskovitz J., Boldes R., Levron J., Erlik Y., Kahana L., and Brandes J.M. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 56 (1991) 213-220
7. Imoedemhe D.A., Sigue A.B., Pacpaco E.L., and Olazo A.B. Stimulation of endogenous surge of luteinizing hormone with gonadotropin-releasing hormone analog after ovarian stimulation for in vitro fertilization. Fertil Steril 55 (1991) 328-332
8. Humaidan P., Ejdrup Bredkjær H., Bungum L., Bungum M., Grøndahl M.L., Westergaard L.G., et al. GnRH agonist (Buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomised study. Hum Reprod 20 (2005) 1213-1220
9. Engmann L., DiLuigi A., Schmidt D., Nulsen J., Maier D., and Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomised controlled study. Fertil Steril 89 (2008) 84-91
10. Griesinger G., Von Otte S., Schroer A., Ludwig A.K., Diedrich K., Al-Hasani S., et al. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective observational proof-of-concept study. Hum Reprod 22 (2007) 1348-1352
11. Babayof R., Margalioth E.J., Huleihel M., Amash A., Zylber-Haran E., Gal M., et al. Serum inhibin A, VEGF and TNFα levels after triggering oocyte maturation with GnRH agonist compared with hCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial. Hum Reprod 21 (2006) 1260-1265
12. Orvieto R. Can we eliminate ovarian hyperstimulation syndrome?. Hum Reprod 20 (2005) 320-322
13. Kol S. Prediction of ovarian hyperstimulation syndrome: why predict if we can prevent!. Hum Reprod 18 (2003) 1557-1558
14. Kol S. Luteolysis induced by a gonadotropin-releasing hormone agonist is the key to prevention of ovarian hyperstimulation syndrome. Fertil Steril 81 (2004) 1-5
15. Kol S., and Itskovitz-Eldor J. Severe OHSS: yes there is a strategy to prevent it!. Hum Reprod 15 (2000) 2266-2267
16. Kolibianakis E.M., Schultze-Mosgau A., Schroer A., Van Steirteghem A., Devroey P., Diedrich K., et al. A lower ongoing pregnancy rate can be expected when GnRH agonist is used for triggering final oocyte maturation instead of hCG in patients undergoing IVF with GnRH antagonists. Hum Reprod 20 (2005) 2887-2892
17. Humaidan P., Bungum L., Bungum M., and Yding Andersen C. Rescue of corpus luteum function with peri-ovulatory hCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 13 (2006) 173-178
18. Griesinger G., Diedrich K., Devroey P., and Kolibianakis E.M. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 12 (2006) 159-168
19. Latouche J., Crumeyrolle-Arias M., Jordan D., Kopp N., Augendre-Ferrante B., Cedard L., et al. GnRH receptors in human granulosa cells: anatomical localization and characterization by autoradiographic study. Endocrinology 125 (1989) 1739-1741
20. Minaretzis D., Jakubowski M., Mortola J.F., and Pavlou S.N. Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J Clin Endocrinol Metab 80 (1995) 430-434
21. Emperaire J.C., Parneix I., and Ruffie A. Luteal phase defects following agonist-triggered ovulation: a patient-dependent response. Reprod Biomed Online 9 (2004) 22-27
22. Penarrubia J., Balasch J., Fabregues F., Creus M., Casamitjana R., Ballesca J.L., et al. Human chorionic gonadotrophin luteal support overcomes luteal phase inadequacy after gonadotrophin-releasing hormone agonist-induced ovulation in gonadotrophin-stimulated cycles. Hum Reprod 13 (1998) 3315-3318
23. Kisicki JC. Pharmacokinetic study of three dosage strengths of COL-1620 with natural progesterone. COL-1620-001US, Columbia Research Laboratories Inc., Serono Product Monograph on Crinone 8%; 11.
24. Colburn WA. Pharmacokinetic study of 90 mg strength of COL-1620 with natural progesterone, BID. COL-1620-002US, Columbia Research Laboratories Inc., Serono Product Monograph on Crinone 8%; 11.
25. Miles R.A., Paulson J.R., Lobo R.A., Press M.F., Dahmoush L., and Sauer M.V. Pharmacokinetics and endometrial tissue levels of progesterone by intramuscular and vaginal routes: a comparative study. Fertil Steril 62 (1994) 485-490
26. Devroey P., Palermo G., Bourgain C., Van Waesberghe L., Smitz J., and Van Steirteghem A.C. Progesterone administration in patients with absent ovaries. Int J Fertil 34 (1989) 188-193
27. Griesinger G., Kolibianakis E.M., Papanikolaou E.G., Diedrich K., Van Steirteghem A., Devroey P., et al. Triggering of final oocyte maturation with gonadotropin-releasing hormone agonist or human chorionic gonadotropin. Live birth after frozen-thawed embryo replacement cycles. Fertil Steril 88 (2007) 616-621
28. Licht P., Russu V., and Wildt L. On the role of human chorionic gonadotropin (hCG) in the embryo-endometrial microenvironment: implications for differentiation and implantation. Semin Reprod Med 19 (2001) 37-47
29. Rao C.V. Multiple novel roles of luteinizing hormone. Fertil Steril 76 (2001) 1097-1100
30. Zelinski-Wooten M.B., Hutchison J.S., Hess D.L., Wolf D.P., and Stouffer R.L. Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys. Hum Reprod 10 (1995) 1658-1666
31. Yding Andersen C., Leonardsen L., Ulloa-Aguirre A., Barrios-De-Tomasi J., Moore L., and Byskov A.G. FSH-induced resumption of meiosis in mouse oocytes: effect of different isoforms. Mol Hum Reprod 5 (1999) 726-731
32. Yding Andersen C. Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles. Reprod Biomed Online 5 (2002) 232-239
33. Stickland S., and Beers W. Studies on the role of plasminogen activator in ovulation. In vitro response of granulosa cells to gonadotrophins, cyclic nucleotides and prostaglandins. J Biol Chem 251 (1976) 5694-5699
34. Eppig J. FSH stimulates hyaluronic acid synthesis by oocyte-cumulus complexes from mouse preovulatory follicle. Nature 281 (1979) 483-486
35. Papanikolaou E.G., Pozzobon C., Kolibianakis E.M., Camus M., Tournaye H., Fatemi H., et al. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 85 (2005) 112-120